Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
ALTEOGEN announced that it is scheduled to receive a milestone payment of USD 15M (approx. KRW 21.94B) following the European marketing authorization of Keytruda SC applied with ALT-B4 licensed to MSD.
📊 [Key Disclosure Details & Major Figures Summary]
- Counterparty: MSD International Business GmbH (MSD)
- Milestone Trigger Event: Receipt of European marketing authorization for ‘Keytruda SC’ (subcutaneous Keytruda) containing ALT-B4 (ingredient name: berahyaluronidase alfa)
- Milestone Amount: USD 15,000,000 (Approx. KRW 21.94B)
- FX rate applied: KRW 1,462.70/USD (SEOUL MONEY BROKERAGE basic rate on November 27, 2025)
- Exceeds 10% of prior fiscal year (FY2024) consolidated revenue (approx. KRW 102.9B), triggering mandatory disclosure
- Expected Payment Schedule: Scheduled for receipt within 30 days from invoice date (November 27, 2025)
- Fact Confirmation / Decision Date: November 27, 2025 (Invoice issuance date)
- Key Terms & Reference:
- No refund obligations for received milestone payments upon agreement termination
- Agreement originally executed in June 2020; amendment signed in February 2024 permitted disclosure of counterparty name (MSD) and target product (Keytruda SC)
- Related Filings: Milestone Payment Receipt (Oct 01, 2025), ALT-B4 License Agreement Amendment (Feb 22, 2024)
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Verification of Milestone Funds Inflow and Additional Commercial Milestone Progress
This disclosure reports the issuance of an invoice for milestone fees following Keytruda SC’s European approval. Confirming the actual receipt of the USD 15M within the 30-day window and tracking subsequent commercial milestones associated with global rollout is essential because it allows investors to verify the concrete financial realization and commercial execution of the technology transfer. Detailed updates can be cross-checked in subsequent periodic filings (Quarterly, Half-Yearly, and Annual Reports).
📢 Disclaimer & Source Notice
Source: This content has been structured and newly created based on official filing data from the Financial Supervisory Service (DART).
Investment Risk Notice: This content is provided for informational and language reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any specific stock. All investment decisions and financial responsibilities rest entirely with the investor.
Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.
